INTRODUCTION
The term acute coronary syndrome refers to a range of acute myocardial ischaemic states. It encompasses unstable angina, non-ST segment elevation myocardial infarction (ST segment elevation generally absent), and ST segment elevation infarction (persistent ST segment elevation usually present). 1 An acute coronary syndrome may occasionally occur in the absence of electrocardiographic changes or elevations in biochemical markers, when the diagnosis is supported by the presence of prior documented coronary artery disease or subsequent confirmatory investigations. 2 In addition to primary prevention efforts, joint guidelines by the American College of Cardiology (ACC) and the American Heart Association (AHA) in 2007 suggest secondary drug prevention measures to be used in patients with ACS. 3, 4 In conjunction with diet and lifestyle modifications, these guidelines suggest the use of statins, beta-blocker, and renin-angiotensin aldosterone system inhibitor drug therapies in ACS patients. 3, 4 Several studies have shown survival benefit when these therapies were given to patients with ACS.
Anti-platelet therapy (aspirin) is the single most costeffective adjunctive therapy for ACS treatment. It decreases mortality in treated patients by 23% (ISIS 2). 5 Multiple controlled trials have demonstrated that β-blocker therapy use for ACS patients decreases both early and late cardiovascular mortality and re-infarction rate, and increases survival by 20 to 40%. [6] [7] [8] [9] [10] The use of ACEI in treating ACS patients reduces mortality postmyocardial infarction by 7% in ISIS-4 trial 11 and by 12% in GISSI-3 trial. 12 The use of lipid-lowering therapy (statin) in ACS patients has revealed decreased rate of progression and modest regression of atheromatous disease in treated patients. It reduces all-cause mortality by 45%. 13 Several guidelines were established to improve care for ACS patients. 14, 15 These guidelines emphasizes the importance of using these pharmacotherapies in managing patients with ACS for secondary prevention.
This study is aimed to show impact of drug utilization on quality of life of ACS patients, i.e., whether not using drugs from all these 5 groups in follow up patients of ACS due to contraindications or drug's side effects would differently affect the quality of life of patients, as measured by "Minnesota living with heart disease questionnaire" 16 as compared to the patients who received drugs from all 5 groups.
MATERIALS AND METHODS
The primary objective is to study the drug utilization pattern in post acute coronary syndrome patients in their follow up visits and secondary objective is to study how drug utilization pattern impacts health outcomes.
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The study protocol, informed consent form (in Bengali, Hindi & English) and case report form (CRF) was submitted to the institutional ethics committee of R.G.Kar Medical College & Hospital, Kolkata for approval. Subject recruitment was commenced only after such approval is obtained.
Written informed consents were taken from each participant according to standard accepted norms. Illiterate individuals gave their fingerprint (left thumb impression) instead of signature in the presence of an appropriate witness.
Study duration-The study was completed within 18 months after commencement. It ran from January 2011 to June 2012. 
Study methodology -
It is a longitudinal prospective unicentric study done at the out patient department of cardiology and at the department of pharmacology, R.G.Kar Medical college, Kolkata.
All prescriptions issued to study subjects attending the cardiology clinic during this whole study period were intercepted after consultation. Number of patients who received drugs from all 5 groups (aspirin, clopidogrel/prasugrel, beta blockers, ACE inhibitor/ARB, statin) were noted as well as patients who were not given drugs from all groups. Patients were asked 21 questions of "Minnesota living with heart disease questionnaire" and scores were calculated in 3 visits of each patient. 1 st visit was 1 week after discharge from hospital, subsequent visits were at 1 months and 3 months following discharge.
For health outcome at different visits, Kruskalwallis test was done to measure effectiveness of therapy of different groups (according to number of essential drug groups prescribed to different patients) and unpaired t test was done to evaluate whether quality of life score reduction differed significantly between these groups.
RESULTS
Total 525 patients were included in this study. 
Pattern of drug use:

Antiplatelet agents:
Aspirin was prescribed to all patients (100%). Among them 120 patients (22.86%) were given 75 mg aspirin per day, 402 patients (76.57%) were given 150 mg aspirin per day, 3 patients were given 300 mg aspirin per day.
Clopidogrel was prescribed in 432 patients (82.29%). Among them 228 (52.78%) were given 75 mg/day and 204 (47.22%) were given 150 mg/day. Prasugrel was given to 84 patients (16%) in 10 mg/day dose.it has been seen that 9 patients out of 525 (1.71%) were not given clopidogrel/ prasugrel.
Beta blockers
Beta blockers were prescribed in 456 patients (86.86%), among them, metoprolol was given in 384 patients 
HMG-Co A reductase inhibitors
Atorvastatin was given to 100% of patients and among them, 72 (13.71%) were given 20 mg/day dose, 276 (52.57%) were given 40 mg/day dose and 177 (33.71%) were given 80 mg/day dose. For health outcomes, we measured the score of "Minnesota living with heart disease questionnaire" on 3 visits of each study subjects, at the initial visit after discharge from hospital, 1 month after that and 3 months after that. There are 21 questions having score range 0 to 5 for each question. Mean score at 1st visit,2nd and 3rd visit were 45.36, 24.29 and 12.94. Comparison between scores at different visits were done by Kruskalwallis test and Dunn's multiple comparison test ( as post hoc test) and it showed very significant reduction in score (p<0.0001) while comparing between each two sets, i.e., between score at 1st visit and score after 1 month, between score at 1st visit and score after 3 months and between score after 1 month and score after 3 months. It indicates satisfactory improvement in quality of life due to drug therapy. This table showed that in patients who were given all the 5 drugs for main indication fared significantly better than those who were not given all drugs.
DISCUSSION
From our study it is clear that incidence of ACS increases with age with a strong trend to peak over 60 years. There is also a very high male:female ratio amongst ACS patients in this study, which is similar to other studies involving patients of acute coronary syndrome. 17, 18 All the prescriptions were intercepted after consultation by a senior consultant cardiologist, thus reducing the impact of prescriber's variables like age, sex, qualifications etc. on prescribing pattern.
There was a high incidence of comorbid conditions like diabetes mellitus, hypertension and smoking among study subjects establishing their role in pathogenesis of ACS.
The number of patients who were prescribed these drugs was high (87%) compared to similar other studies. The studies in Hyderabad, Saudi Arabia and Spain showed use of ACE inhibitors only in 45.71%, 59%, 32% respectively. A strong correlation was found regarding prescription of this group of drugs and presence of diabetes mellitus.
Number of subjects prescribed beta blockers is quite satisfactory (86.86%) compared to other similar studies. The studies in Hyderabad
19
, Saudi Arabia 20 and Spain 21 showed use of beta blockers in only 60%, 69% and 50.2% patients respectively.
And while comparing the score of "Minnesota living with heart disease questionnaire" on 3 visits of each study subjects, it has been found though there is overall significant satisfactory improvement with drug therapy. But while comparing the improvement over time between 2 groups (patients who were not prescribed drugs from all the 5 groups for main indication and patients who were given all the 5 drug groups), it was found that improvement over time is very significant in the latter group. It indicates that drugs from all these 5 groups must be given to all follow up patients of ACS, unless contraindicated as they significantly improve quality of life of the patients with heart disease and this beneficial effect is additive with each drug group.
CONCLUSIONS
The quality of prescriptions among this important group of patients was very good compared to similar other studies, done in India or abroad.
There is overall significant satisfactory improvement with drug therapy.
Prescription of all 5 drug groups (as per AHA/ACC 2007 guidelines) has significant better outcome in quality of life score than prescription of less than 5 drug groups.
